Type II, which includes pancreatic pheochromocytoma and islet cell tumors in addition to retinal and CNS angioblastomas, has a higher risk of PHEO and is characterized by VHL missense mutations (1, 2, 8), resulting in only single amino acid changes in VHL protein. Here, VHL is linked to pancreatic neuroendocrine tumor.